Orthocell Posts Record U.S. Monthly Sales for Nerve Wrap Device
Australian medtech firm Orthocell recorded its strongest U.S. month for Remplir™, selling 92 units in October 2026.
Australian medical device maker Orthocell Ltd reported its highest single-month U.S. sales figures since the commercial launch of Remplir™, its FDA-cleared collagen nerve wrap, with 92 units sold in October 2026. The milestone signals accelerating market penetration for a product the company is positioning as a category leader in peripheral nerve repair.
Remplir™ is engineered to support the repair and protection of peripheral nerves, wrapping damaged nerves in collagen to aid recovery. The device is designed and manufactured in Australia before being distributed into international markets, including the United States, where FDA clearance has been a critical gateway to commercial growth.
Read more EFICYENT to Attend Singapore FinTech Festival 2026 →
The October result represents a measurable inflection point for Orthocell's U.S. commercial strategy. Peripheral nerve repair is a specialized surgical segment, and consistent monthly volume gains in such a niche market typically reflect both growing surgeon adoption and expanding institutional access — dynamics that analysts often watch as leading indicators of longer-term revenue trajectory.
Orthocell has described Remplir™ as an emerging category leader in key international markets, a claim the October sales figure appears to reinforce as the company builds its presence against established competitors in the nerve repair space. The FDA-cleared status remains central to its U.S. marketing proposition.
Continue reading at All Financial Services & Investing.
